Close Menu

Precision Oncology News: Breaking News

Regulators approved the PARP inhibitor as a monotherapy for BRCA1/2-mutated mCRPC and together with Avastin for advanced, HRD-positive ovarian cancer.

The company licensed the FGFR2 inhibitor from BridgeBio Pharma for development and commercialization in Mainland China, Hong Kong, and Macau.

Trodelvy's clinical development in China, led by Everest Medicines, follows the agent's US accelerated approval in April for triple-negative breast cancer. 

Cancer centers are investing in testing and decision support tools to personalize cancer care, though the COVID-19 pandemic has presented challenges.

The Phase III trial will compare Enhertu against Kadcyla as an adjuvant treatment for early-stage HER2-positive breast cancer patients.

The agency ordered Poseida to halt the trial in August after a patient died but is now allowing the company to resume the study with an amended protocol.

Tempus is developing a new predictive bioinformatics model to improve clinical trial enrollment for Janssen, while the pharma firm has joined Tempus' TIME Trial.

The Phase I/II trials will study Reqorsa in combination with Merck's Keytruda and AstraZeneca's Tagrisso in certain molecularly defined lung cancer subgroups.

The company has begun Phase II trials of its bespoke treatment GRANITE and the off-the-shelf counterpart SLATE in combination with BMS's checkpoint inhibitors.  

The agreement will initially focus on making available assays developed and validated by LabCorp's Covance business, with the first assays targeting oncology.

The INTERCEPT study showed the potential of broader genetic testing to personalize treatment approaches for cancer patients.

The partnership will leverage VieCure's artificial intelligence platform and TD2's clinical trial services to bring precision oncology to the community setting.

The two companies will create a platform that combines drug screening services and cancer genomic profiling to help oncologists choose the right treatment for their patients.

The collaborators will work on advancing lung cancer antibodies that selectively target NRP2 isoforms, which have been linked to aggressive disease.

Roche's real-time PCR test detects defined mutations of the epidermal growth factor receptor gene in DNA from non-small cell lung cancer patients.

The companies said their partnership will allow pharmaceutical partners to measure both ctDNA and CTC biomarkers from a single blood draw when conducting drug trials.

Inivata's Radar assay will be used to monitor circulating tumor DNA from multiple tumor types in trial participants following treatment with Maverick's MVC-101 candidate. 

The FDA also granted priority review for Enhertu for the treatment of patients with HER2-positive metastatic gastric cancer.

The FIDES-03 trial will assess derazantinib plus Lilly's anti-VEGFR2 drug for patients with advanced gastric cancer harboring FGFR genetic aberrations.

Based on the results of this Phase Ib/II trial, the drugmaker will explore the activity of TG4001 in a larger confirmatory study.

The Phase I/II GOBLET trial will assess pelareorep plus Tecentriq in pancreatic, colorectal, and anal cancer patients and explore biomarkers of response.

The funds will support continued growth in precision oncology, new product development, and new initiatives in the clinical trial and biopharmaceutical markets.

The company also acquired DNA methylation analysis firm Base Genomics for $410 million and said it plans to raise $869 million in a direct stock offering.

FoundationOne Liquid CDx can now be used as a companion diagnostic for therapies to treat advanced ovarian, breast, and non-small cell lung cancer.

The company hopes to expand the reach of precision oncology to more patients and find novel drugs and targets for untreatable cancers.